Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Atrium Therapeutics, Inc.NASDAQ: RNA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents of $267.85M in Q1 FY2026
Q1 FY2026 cash & equivalents was $267.85M.
Context
- Cash & equivalents amounted to 91.6% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 270M USD
- Year-over-year change
- —
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 270M | — |
Cash & Equivalents vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Cash & Equivalents figures are available to compare.
Balance Sheet
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.